Michael Pearson is to step down as  chairman of the board and chief executive officer of Valeant Pharmaceuticals International Inc.   The company has appointed activist investor William Ackman to its board. Photograph: Reuters

As recently as last summer, J Michael Pearson styled himself as a brash and bold executive with a new way of thriving in pharmaceuticals: buying othe(...)

Michael Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International, who has returned from a two-month absence due to illness. Photographer: Scott Eells/Bloomberg

Valeant Pharmaceuticals is withdrawing its financial forecast and will delay releasing fourth-quarter results, as chief executive Michael Pearsonretur(...)

Mike Pearson: hard-driving boss Valeant boss ensured the group has, over the past eight years, bought one drug company after another. Photograph:  Scott Eells/Bloomberg

What is the right way to build up a drug company? Do you take the traditional route, investing in your own research and development and seeking to dis(...)

The drug could cost women as much as $400 per month

Valeant Pharmaceuticals agreed to pay about $1 billion (€895 million) in cash for Sprout Pharmaceuticals, the US pharmaceutical group that this week r(...)

Valeant Pharmaceuticals, the Canadian drugmaker known for its serial acquisitions, reported first-quarter profit that topped analysts’ estimates and r(...)

In Dublin Ryanair rose by more than 1.3 per cent as investors greeted the news that its board has ratified a push into the transatlantic market in coming years

Germany’s Dax raced to record highs on Monday, part of an extended rally of the European stock market driven by investors’ expectations that a weaken(...)

Michael “Mike” Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International. It increased its offer for US based Salix Pharmaceuticals to $10.96 billion in cash, topping Dublin based Endo International’s bid of $10.93 billion. (Photograph: Scott Eells/Bloomberg)

Valeant Pharmaceuticals International said it increased its offer for US based Salix Pharmaceuticals to $10.96 billion in cash, topping Dublin based E(...)

The acquisition is the latest in a spate of big pharma deals this year as many companies are strengthening their portfolios as old drugs go generic

AbbVie is to buy Pharmacyclics for about $21 billion, giving it access to what is expected to be one of the world’s top-selling cancer drugs and expan(...)

The Salix deal termination came less than two weeks after the US treasury department took a series of steps to curb “inversion” deals that let companies avoid US taxes by reincorporating abroad.

One US pharma company called off it Irish-based “inversion” merger yesterday in response to US Treasury measurers, while another restructured its deal(...)

Salix cited “changed political environment” in decision to abandon deal

Salix Pharmaceuticals and Italy’s Cosmo Pharmaceuticals have ended a $2.7 billion merger agreement that would have given the US company an Irish ba(...)

  • 1
  • 2
  • Next
  • Last »